INSM - Insmed Inc Stock Price, Fair Value and News

74.53USD+0.03 (+0.04%)Market Closed

Market Summary

USD74.53+0.03

Market Closed

0.04%

INSM Stock Price

View Fullscreen

INSM RSI Chart

INSM Valuation

Market Cap

11.1B

Price/Earnings (Trailing)

-14.83

Price/Sales (Trailing)

35.11

EV/EBITDA

-17.42

Price/Free Cashflow

-18.82

INSM Price/Sales (Trailing)

INSM Profitability

EBT Margin

-235.89%

Return on Equity

160.69%

Return on Assets

-64.44%

Free Cashflow Yield

-5.31%

INSM Fundamentals

INSM Revenue

Revenue (TTM)

315.5M

Rev. Growth (Yr)

15.77%

Rev. Growth (Qtr)

-9.79%

INSM Earnings

Earnings (TTM)

-746.9M

Earnings Growth (Yr)

1.67%

Earnings Growth (Qtr)

15.57%

Breaking Down INSM Revenue

Last 7 days

-1.9%

Last 30 days

8.1%

Last 90 days

200.5%

Trailing 12 Months

265.3%

How does INSM drawdown profile look like?

INSM Financial Health

Current Ratio

1.8

Debt/Equity

-2.02

Debt/Cashflow

-0.61

INSM Investor Care

Shares Dilution (1Y)

8.92%

Diluted EPS (TTM)

-5.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	315.5M	0	0	0
2023	257.5M	269.5M	280.8M	305.2M
2022	201.4M	221.2M	242.2M	245.4M
2021	167.8M	170.6M	173.8M	188.5M
2020	151.4M	163.9M	168.7M	164.4M
2019	37.2M	64.5M	100.6M	136.5M
2018	3.5M	6.1M	8.5M	17.3M
2017	588.0K	593.0K	781.0K	1.6M
2016	408.0K	504.0K	567.0K	604.0K
2015	4.0M	2.1M	178.0K	261.0K
2014	9.6M	7.7M	5.8M	0
2013	5.3M	7.4M	9.4M	11.5M
2012	3.2M	0	0	0
2011	6.6M	5.7M	4.3M	4.4M
2010	0	9.2M	8.1M	6.9M
2009	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Insmed Inc

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

CEO	Mr. William H. Lewis J.D., M.B.A.
WEBSITE	insmed.com
INDUSTRY	Biotechnology
EMPLOYEES	736

Insmed Inc Frequently Asked Questions

What is the ticker symbol for Insmed Inc? What does INSM stand for in stocks?

INSM is the stock ticker symbol of Insmed Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Insmed Inc (INSM)?

As of Fri Jul 26 2024, market cap of Insmed Inc is 11.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of INSM stock?

You can check INSM's fair value in chart for subscribers.

Is Insmed Inc a good stock to buy?

The fair value guage provides a quick view whether INSM is over valued or under valued. Whether Insmed Inc is cheap or expensive depends on the assumptions which impact Insmed Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INSM.

What is Insmed Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, INSM's PE ratio (Price to Earnings) is -14.83 and Price to Sales (PS) ratio is 35.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. INSM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Insmed Inc's stock?

In the past 10 years, Insmed Inc has provided 0.156 (multiply by 100 for percentage) rate of return.